NCT02143466 2026-01-30
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
AstraZeneca
Canadian Cancer Trials Group
OHSU Knight Cancer Institute
The Christie NHS Foundation Trust
Cancer Research UK
AstraZeneca
AstraZeneca